Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control After Acute Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT02607943

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02607943
Other papers using this trial's data
  • A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care Scientific reports, 2021-06-01 DOI, PubMed 34075142, PMC8169927 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02607943. Randomized; no masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2018-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control After Acute Stroke
Acronym
ICAS
Condition
Acute Stroke
Condition
Hyperglycemia
Intervention (Drug)
Insulin Glargine
Intervention (Drug)
Regular Insulin
Lead sponsor
National Taiwan University Hospital (class: other)
Collaborator
Chang Gung Memorial Hospital (class: other)
Collaborator
Taipei Medical University Shuang Ho Hospital (class: other)

Record details

Record id
cardio:ct-nct02607943
Content hash
aea39e5e0e9c3b08adc6d6aaececd9b800f291e92b2cc033c1b20118d036e0d3